Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. Farooqui MZ, et al. Among authors: hughes te. Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9. Epub 2014 Dec 31. Lancet Oncol. 2015. PMID: 25555420 Free PMC article. Clinical Trial.
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.
Desai S, Mo C, Gaglione EM, Yuan CM, Stetler-Stevenson M, Tian X, Maric I, Wake L, Farooqui MZ, Drinkwater DC, Soto S, Valdez J, Hughes TE, Nierman P, Lotter J, Marti GE, Pleyer C, Sun C, Superata J, Nichols C, Herman SEM, Lindorfer MA, Taylor RP, Wiestner A, Ahn IE. Desai S, et al. Among authors: hughes te. Leuk Lymphoma. 2021 Aug;62(8):1816-1827. doi: 10.1080/10428194.2021.1888379. Epub 2021 Mar 2. Leuk Lymphoma. 2021. PMID: 33653216 Free PMC article. Clinical Trial.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A. Ahn IE, et al. Among authors: hughes te. Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26. Blood. 2018. PMID: 29483101 Free PMC article. Clinical Trial.
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
Herndon TM, Chen SS, Saba NS, Valdez J, Emson C, Gatmaitan M, Tian X, Hughes TE, Sun C, Arthur DC, Stetler-Stevenson M, Yuan CM, Niemann CU, Marti GE, Aue G, Soto S, Farooqui MZH, Herman SEM, Chiorazzi N, Wiestner A. Herndon TM, et al. Among authors: hughes te. Leukemia. 2017 Jun;31(6):1340-1347. doi: 10.1038/leu.2017.11. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074063 Free PMC article.
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, Keyvanfar K, Gibellini F, Valdez J, Boss C, Samsel L, McCoy JP Jr, Wilson WH, Pittaluga S, Wiestner A. Aue G, et al. Haematologica. 2009 Sep;94(9):1266-73. doi: 10.3324/haematol.2009.005835. Haematologica. 2009. PMID: 19734418 Free PMC article. Clinical Trial.
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, Kim DY, Ghannam JY, Oetjen KA, Destefano CB, Smith DM, Tekleab H, Li Y, Dagur P, Hughes T, Marté JL, Del Rivero J, Klubo-Gwiezdzinksa J, Gulley JL, Calvo KR, Lai C, Hourigan CS. Goswami M, et al. J Immunother Cancer. 2022 Jan;10(1):e003392. doi: 10.1136/jitc-2021-003392. J Immunother Cancer. 2022. PMID: 35017151 Free PMC article.
Haematopoietic stem cell transplant patients have a high initial failure rate to hepatitis B vaccination that can be overcome with subsequent vaccination series.
Shalabi RA, Worst MA, Hughes TE, Walsh-Chocolaad T, Cook L, Gunn K, Wells B, Ciurea R, Aue G, Tian X, Childs RW. Shalabi RA, et al. Among authors: hughes te. Br J Haematol. 2022 Mar;196(6):1404-1407. doi: 10.1111/bjh.17991. Epub 2021 Dec 8. Br J Haematol. 2022. PMID: 34881432 No abstract available.
199 results